Who
Peter Altman
President and CEO
Company insider
Files Form 4 as: President and CEO, BioCardia.
In numbers
- Trades disclosed
- 216
- Buys
- 144
- Sells
- 1
- Bought
- $687K
- Sold
- $7,392
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Feb 2018
- Last trade
- 16 Oct 2026
- Last filed
- 20 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Oct 2026filed 20 Oct 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $285300 at $0.95 | filing |
| 15 Oct 2026filed 20 Oct 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $190200 at $0.95 | filing |
| 29 Sep 2026filed 30 Sep 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $1,0301,000 at $1.03 | filing |
| 29 Sep 2026filed 30 Sep 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $1,0301,000 at $1.03 | filing |
| 23 Sep 2026filed 23 Sep 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $1,9951,900 at $1.05 | filing |
| 23 Sep 2026filed 23 Sep 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $1,9951,900 at $1.05 | filing |
| 3 Sep 2026filed 4 Sep 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $872800 at $1.09 | filing |
| 3 Sep 2026filed 4 Sep 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $872800 at $1.09 | filing |
| 17 Aug 2026filed 18 Aug 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $5,0225,400 at $0.93 | filing |
| 17 Aug 2026filed 18 Aug 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $5,0225,400 at $0.93 | filing |
| 13 Aug 2026filed 13 Aug 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $1,7481,900 at $0.92 | filing |
| 13 Aug 2026filed 13 Aug 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $1,7481,900 at $0.92 | filing |
| 29 Jul 2026filed 29 Jul 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $3,9005,000 at $0.78 | filing |
| 29 Jul 2026filed 29 Jul 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $3,9005,000 at $0.78 | filing |
| 17 Jul 2026filed 20 Jul 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $415500 at $0.83 | filing |
| 17 Jul 2026filed 20 Jul 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $415500 at $0.83 | filing |
| 15 Jul 2026filed 15 Jul 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $1,2901,500 at $0.86 | filing |
| 15 Jul 2026filed 15 Jul 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $1,2901,500 at $0.86 | filing |
| 14 Jul 2026filed 15 Jul 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $2,4642,800 at $0.88 | filing |
| 14 Jul 2026filed 15 Jul 2026 | BCDA BioCardiaBiotechnology | SEC FORM 4 Bought | $2,4642,800 at $0.88 | filing |
News
BioCardia (NASDAQ:BCDA) Stock Falls 5.5% – What's Next?BCDA · dailypolitical.com · 23 Oct 2026BioCardia Advances Helix Catheter Toward FDA Marketing ClearanceBCDA · rttnews.com · 19 Oct 2026BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this QuarterBCDA · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Peter Altman; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.